Physician profile
Wayne Greene
NPI 1881705879
$3,344.15
in general payments reported to CMS, 2019-2025
30 companies · $24.35 in 2025
The $24.35 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $254 · 2021: $1,145 · 2022: $549 · 2023: $714 · 2024: $15.59 · 2025: $24.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570 · Consulting Fee: $150 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.55 |
| Consulting Fee | $150.00 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,025.76 | 2019-2023 | Tysabri, Vumerity, Avonex |
| Biohaven Pharmaceuticals, INC. | $411.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $272.47 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $224.36 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $172.00 | 2019-2023 | Ultomiris |
| Ucb, INC. | $169.30 | 2019-2023 | Briviact |
| Neurocrine Biosciences, INC. | $118.06 | 2020-2023 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $99.63 | 2021-2023 | |
| Abbvie INC. | $97.89 | 2021-2024 | |
| Eisai INC. | $79.12 | 2019-2023 | |
| Lilly USA, LLC | $76.80 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $68.01 | 2019-2020 | |
| Amgen INC. | $63.61 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $53.04 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $50.91 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $43.78 | 2022-2023 | Zeposia |
| Acorda Therapeutics, INC | $43.54 | 2019 | |
| Acadia Pharmaceuticals INC | $39.41 | 2019-2023 | Nuplazid |
| Aprecia Pharmaceuticals, LLC | $31.10 | 2023 | Spritam |
| Emd Serono, INC. | $30.09 | 2020-2023 | Mavenclad |
| Genentech USA, INC. | $28.52 | 2019-2023 | Ocrevus |
| Genzyme Corporation | $25.73 | 2019-2020 | |
| Boston Scientific Corporation | $24.35 | 2025 | Avvigo Guidance System |
| Impel Pharmaceuticals INC. | $14.77 | 2022 | |
| Pfizer INC. | $14.32 | 2023 | |
| Grifols USA, LLC | $14.31 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.42 | 2019 | |
| Argenx US, INC. | $13.07 | 2023 | Vyvgart |
| Adamas Pharmaceuticals, INC. | $12.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.